Optimer Pharmaceuticals (OPTR) Tops Q3 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts OPTR Hot Sheet
Price: $12.78 --0%
Financial Fact:
Consolidated net income (loss): -26.87M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Financial Fact:
Consolidated net income (loss): -26.87M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Optimer Pharmaceuticals (NASDAQ: OPTR) reported Q3 EPS of ($0.56), $0.08 better than the analyst estimate of ($0.64). Revenue for the quarter came in at $17.89 million versus the consensus estimate of $16.03 million.
For earnings history and earnings-related data on Optimer Pharmaceuticals (OPTR) click here.
For earnings history and earnings-related data on Optimer Pharmaceuticals (OPTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- Arm Holdings stock sinks amid broad chip sector selloff
- Freedom Broker Downgrades RPC Inc. (RES) to Sell
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
